Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regenxbio Inc (NQ: RGNX )

9.180 -0.450 (-4.67%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 699,201
Open 9.380
Bid (Size) 9.200 (1)
Ask (Size) 9.500 (1)
Prev. Close 9.630
Today's Range 9.080 - 9.700
52wk Range 8.535 - 28.80
Shares Outstanding 43,466,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Going On With REGENXBIO Shares Monday?
REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy. 
Via Benzinga
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
Via Benzinga

Performance

YTD
-49.95%
-49.95%
1 Month
-11.48%
-11.48%
3 Month
-24.82%
-24.82%
6 Month
-40.66%
-40.66%
1 Year
-53.87%
-53.87%

More News

Read More
5 Analysts Have This To Say About Regenxbio
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
What 4 Analyst Ratings Have To Say About Regenxbio
Via Benzinga
Assessing Regenxbio: Insights From 5 Financial Analysts
Via Benzinga
Where Regenxbio Stands With Analysts
Via Benzinga
Assessing Regenxbio: Insights From 4 Financial Analysts
Via Benzinga
Evaluating Regenxbio: Insights From 9 Financial Analysts
Via Benzinga
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
Via FinancialNewsMedia
Exposures COVID-19
7 Biotech Stocks to Buy for Their Game-Changing Potential
Via InvestorPlace
Why Is Clearside Biomedical Stock Gaining Today?
Via Benzinga
7 Biotech Stocks to Buy on the Dip: June 2024
Via InvestorPlace
Where Regenxbio Stands With Analysts
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock
Via Benzinga
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
Via Benzinga
Exposures Product Safety
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
Via Investor's Business Daily
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Via Investor's Business Daily
Exposures Product Safety
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Via Benzinga
RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Via The Motley Fool
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
Via Benzinga
REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.